4d pharma (4d pharma) Earnings per Share (Diluted) : $0.00 (TTM As of Dec. 2021)

View and export this data going back to 2021. Start your Free Trial

What is 4d pharma Earnings per Share (Diluted)?

4d pharma's Earnings per Share (Diluted) for the six months ended in Dec. 2021 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00.

4d pharma's EPS (Basic) for the six months ended in Dec. 2021 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00.

4d pharma's EPS without NRI for the six months ended in Dec. 2021 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 6.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -7.80% per year.

During the past 8 years, 4d pharma's highest 3-Year average EPS without NRI Growth Rate was 10.10% per year. The lowest was -87.00% per year. And the median was -32.20% per year.

4d pharma Earnings per Share (Diluted) Historical Data

The historical data trend for 4d pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Earnings per Share (Diluted) Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Earnings per Share (Diluted)

Get a 7-Day Free Trial

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Earnings per Share (Diluted)	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of 4d pharma's Earnings per Share (Diluted)

For the Biotechnology subindustry, 4d pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4d pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where 4d pharma's PE Ratio falls into.

4d pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

4d pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-71.755	-	0)	/	0
	=

4d pharma's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (Q: Dec. 2021 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-47.803	-	0)	/	0
	=

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

4d pharma (OTCPK:LBPWQ) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

4d pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of 4d pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (4d pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.